Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy - Report of a case

Vidmer Scaioli, Augusto Caraceni, Cinzia Martini, Elena Palazzini, Emiliana Tarenzi, Fabio Fulfaro, Elisabetta Munzone

Research output: Contribution to journalArticle

Abstract

The case of a 63 year-old woman affected by advanced breast cancer is reported. Chemotherapy with paclitaxel (200 mg/m2) and doxorubicin (60 mg/m2) every three weeks was given for 8 cycles. The patient progressively developed a sensory-motor neuropathy of axonal type. After the 6th chemotherapy cycle the patient complained of subjective visual symptoms without a relevant reduction of visual acuity. Visual evoked potentials (VEPs) showed an important reduction of the amplitude of the P100 component with a less pronounced delay in latency. Electroretinic responses were normal. These findings suggest an optic neuropathy, confirming previous reports of the occurrence of optic nerve involvement in course of paclitaxel chemotherapy. The role of VEP assessment in course of paclitaxel chemotherapy is discussed comparing clinical and neurophysiological findings in this case with three previously reported cases.

Original languageEnglish
Pages (from-to)221-225
Number of pages5
JournalJournal of Neuro-Oncology
Volume25
Issue number3
DOIs
Publication statusPublished - Oct 1995

Fingerprint

Visual Evoked Potentials
Paclitaxel
Combination Drug Therapy
Doxorubicin
Drug Therapy
Optic Nerve Diseases
Optic Nerve
Visual Acuity
Breast Neoplasms

Keywords

  • breast cancer
  • neurotoxicity
  • optic neuropathy
  • paclitaxel
  • peripheral neuropathy
  • visual evoked potentials

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy - Report of a case. / Scaioli, Vidmer; Caraceni, Augusto; Martini, Cinzia; Palazzini, Elena; Tarenzi, Emiliana; Fulfaro, Fabio; Munzone, Elisabetta.

In: Journal of Neuro-Oncology, Vol. 25, No. 3, 10.1995, p. 221-225.

Research output: Contribution to journalArticle

@article{cbc58366e039418cb9c33e46892053c1,
title = "Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy - Report of a case",
abstract = "The case of a 63 year-old woman affected by advanced breast cancer is reported. Chemotherapy with paclitaxel (200 mg/m2) and doxorubicin (60 mg/m2) every three weeks was given for 8 cycles. The patient progressively developed a sensory-motor neuropathy of axonal type. After the 6th chemotherapy cycle the patient complained of subjective visual symptoms without a relevant reduction of visual acuity. Visual evoked potentials (VEPs) showed an important reduction of the amplitude of the P100 component with a less pronounced delay in latency. Electroretinic responses were normal. These findings suggest an optic neuropathy, confirming previous reports of the occurrence of optic nerve involvement in course of paclitaxel chemotherapy. The role of VEP assessment in course of paclitaxel chemotherapy is discussed comparing clinical and neurophysiological findings in this case with three previously reported cases.",
keywords = "breast cancer, neurotoxicity, optic neuropathy, paclitaxel, peripheral neuropathy, visual evoked potentials",
author = "Vidmer Scaioli and Augusto Caraceni and Cinzia Martini and Elena Palazzini and Emiliana Tarenzi and Fabio Fulfaro and Elisabetta Munzone",
year = "1995",
month = "10",
doi = "10.1007/BF01053155",
language = "English",
volume = "25",
pages = "221--225",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy - Report of a case

AU - Scaioli, Vidmer

AU - Caraceni, Augusto

AU - Martini, Cinzia

AU - Palazzini, Elena

AU - Tarenzi, Emiliana

AU - Fulfaro, Fabio

AU - Munzone, Elisabetta

PY - 1995/10

Y1 - 1995/10

N2 - The case of a 63 year-old woman affected by advanced breast cancer is reported. Chemotherapy with paclitaxel (200 mg/m2) and doxorubicin (60 mg/m2) every three weeks was given for 8 cycles. The patient progressively developed a sensory-motor neuropathy of axonal type. After the 6th chemotherapy cycle the patient complained of subjective visual symptoms without a relevant reduction of visual acuity. Visual evoked potentials (VEPs) showed an important reduction of the amplitude of the P100 component with a less pronounced delay in latency. Electroretinic responses were normal. These findings suggest an optic neuropathy, confirming previous reports of the occurrence of optic nerve involvement in course of paclitaxel chemotherapy. The role of VEP assessment in course of paclitaxel chemotherapy is discussed comparing clinical and neurophysiological findings in this case with three previously reported cases.

AB - The case of a 63 year-old woman affected by advanced breast cancer is reported. Chemotherapy with paclitaxel (200 mg/m2) and doxorubicin (60 mg/m2) every three weeks was given for 8 cycles. The patient progressively developed a sensory-motor neuropathy of axonal type. After the 6th chemotherapy cycle the patient complained of subjective visual symptoms without a relevant reduction of visual acuity. Visual evoked potentials (VEPs) showed an important reduction of the amplitude of the P100 component with a less pronounced delay in latency. Electroretinic responses were normal. These findings suggest an optic neuropathy, confirming previous reports of the occurrence of optic nerve involvement in course of paclitaxel chemotherapy. The role of VEP assessment in course of paclitaxel chemotherapy is discussed comparing clinical and neurophysiological findings in this case with three previously reported cases.

KW - breast cancer

KW - neurotoxicity

KW - optic neuropathy

KW - paclitaxel

KW - peripheral neuropathy

KW - visual evoked potentials

UR - http://www.scopus.com/inward/record.url?scp=0028851948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028851948&partnerID=8YFLogxK

U2 - 10.1007/BF01053155

DO - 10.1007/BF01053155

M3 - Article

C2 - 8592172

AN - SCOPUS:0028851948

VL - 25

SP - 221

EP - 225

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -